Can cyclodextrins and dextrans revolutionize gut health?

Today's cyclodextrin,

This review highlights the exciting potential of these compounds to support the gut microbiome. Conducted in collaboration with Université Clermont Auvergne, the study was authored by Anna G. and Emmanuelle Lainé, under the supervision of Judyta Cielecka-Piontek.

It explores how cyclodextrins and dextrans can promote the growth of beneficial bacteria like Bifidobacterium and Lactobacillus and enhance the production of short-chain fatty acids essential for gut health. This review also sheds light on their overlooked prebiotic potential.

The gut microbiome plays a key role in digestion, metabolism, and overall vitality.

Dive into the insights provided in this comprehensive review: How Do Cyclodextrins and Dextrans Affect the Gut Microbiome? Review of Prebiotic Activity

Preparation of ingredients for producing bread with reduced glycemic index 

Today's cyclodextrin,

Today’s cyclodextrin is about producing bread, of course, with a low glycemic index.

This invention from Universidad de Granada describes a preparation of ingredients that includes alpha-cyclodextrin and other ingredients. These ingredients permit the production of a dough suitable for traditional processing and making bread with a reduced glycemic index.

This preparation adds at least 5 g ACD to 50 g starch.

In the Scientific Opinion of the Panel on Dietetic Products, Nutrition and Allergies of the European Food Safety Authority (EFSA), two intervention studies showed that alpha-cyclodextrin added to starch significantly affected the postprandial glycemic response without disproportionately increasing the postprandial insulin response. This did not occur when it was added to sucrose.

Based on the data presented, the Panel concluded that a cause-and-effect relationship is established between the consumption of alpha-cyclodextrin with starch-containing meals and a reduction of postprandial glycemic response. The panel considers that at least 5 g of alpha-cyclodextrin per 50 g of starch should be consumed to obtain the claimed effect.

The target population of this health claim is adults who wish to reduce their postprandial glycemic response [EFSA. Scientific Opinion on the substantiation of health claims related to alpha-cyclodextrin and reduction of post-prandial glycaemic responses (ID 2926, further assessment) according to Article 13 (1) of Regulation (EC) No 1924/2006. EFSA Journal 2012 10 (6): 2713].

You can read the patent here: Espacenet – Description

carbohyde, alfa-cyclodextrin, producing bread

Direct Continuous Flow Synthesis of Two Difficult Polypeptides Using β-Cyclodextrins

Today's cyclodextrin,

Direct Continuous Flow Synthesis of Two Difficult Polypeptides Using β-Cyclodextrins

Wonderful paper from Hungary by Szaniszló Szebasztián, Gitta Schlosser, Viktor Farkas and Perczel András

Results show that the use of β-CyD as an additive results in a significant (8–19%) increase in the purity of the crude polypeptide compared to that determined by our reference method.

Direct Continuous Flow Synthesis of Two Difficult Polypeptides Using β-Cyclodextrins | The Journal of Organic Chemistry

Cationic Cyclodextrin-Based Carriers for Drug and Nucleic Acid Delivery

Today's cyclodextrin, drug delivery

Check out our latest cyclodextrin review fresh from the oven on cationic cyclodextrins for drug and nucleic acid delivery.

This contribution to science is a fruit of our collaboration with Eötvös Loránd University and Semmelweis University (Szabolcs Béni and Adila Nazli).

Special thanks to Milo Malanga PhD and Tamas Sohajda as well as Bicyclos HEurope for the funding.

Cationic Cyclodextrin-Based Carriers for Drug and Nucleic Acid Delivery

Cationic Cyclodextrin-Based Carriers for Drug and Nucleic Acid Delivery

Disulfide stoppered polyrotaxanes with enhanced cellular uptake and intracellular cyclodextrin release

Today's cyclodextrin,

Today’s cyclodextrin:
Polyrotaxanes are molecular necklaces composed of polymers, threaded macrocycles, and bulky stopper molecules to inhibit the decomposition of the first two.

These supramolecular assemblies are promising active ingredients for treating lysosomal storage disorders.

This study aimed to synthesize such polyrotaxanes with a novel, simple method, resulting in high threading efficacy, enhanced cellular uptake, and intracellular cyclodextrin (CD) release.

Great work from Andreas Bernkop-Schnürch, Gergely Kali and their team at Bernkop-Schnürch Research Group.

Disulfide stoppered polyrotaxanes with enhanced cellular uptake and intracellular cyclodextrin release – ScienceDirect

Disulfide stoppered polyrotaxanes with enhanced cellular uptake and intracellular cyclodextrin release

Anti-inflammatory effects of cyclodextrin nanoparticles enable macrophage repolarization and reduce inflammation

Today's cyclodextrin,

Fantastic antiinflammatory cyclodextrin application by Goethe University Frankfurt

Inflammation plays a critical role in the pathophysiology of many diseases, and dysregulation of the involved signaling cascades often culminates in uncontrollable disease progression and, ultimately, chronic manifestation.

Cyclodextrins (CDs), particularly β-CD, have gained attention as biocompatible biomaterials with intrinsic anti-inflammatory properties, and chemical modification of their backbone offers a promising strategy to enhance their physicochemical properties, adaptability, and therapeutic potential.

In a human macrophage model, CD nanoparticles demonstrated superior anti-inflammatory activity, with derivative-specific effects tied to their physicochemical properties, surpassing the soluble β-CD control.

The findings of this study underscore the potential of cyclodextrin-based nanoparticles as versatile biomaterials for treating the complex pathophysiology of various acute and chronic inflammation-associated disorders.
Anti-inflammatory effects of cyclodextrin nanoparticles enable macrophage repolarization and reduce inflammation | Discover Nano

 A method of improving sleep quality and/or subsequent behavioural outcomes

Today's cyclodextrin

We all need a nice good night sleep, so today’s cyclodextrin is about our recent patent using CDs in such an application.

Nestlé‘s researchers, Francois-Pierre MARTIN, Christian Darimont, Celia Repond(-Francey) and Norman Moullan, developed a formula to improve sleep quality, containing – among other components – alpha-cyclodextrin mainly to help lowering the glycemic response of the last meal.

Of course, there is a lot you can do to improve your sleep, even without cyclodextrins. Personally, those would be my first choices.

US20240390444 COMPOSITIONS AND METHODS LOWERING GLYCEMIC RESPONSE TO IMPROVE SLEEP QUALITY AND/OR SUBSEQUENT BEHAVIOURAL OUTCOMES

Structure-activity relationship of modified amphiphilic cationic cyclodextrins for enhanced siRNA delivery

Egyéb kategória, Today's cyclodextrin, ,

Today’s cyclodextrin was a little gift under CarboHyde’s and GENEGUT’s Christmas tree.

This study identified the structural modifications that enhance gene delivery activity of a range of cationic amphiphilic CDs, including both β- and γ-CD.

Each CDs incorporated a C12 lipid chain on the primary face of the CD. On the secondary rim, at positions C2 and C3, either primary or tertiary amine groups.

A comparative in vitro study was conducted to assess the gene silencing efficacy of these nanoparticles using the luciferase reporter gene in A549-luc cells.

Gene silencing levels for both β- and γ-CDs increased when modified with a primary amine compared to a tertiary amine group at position C2. Gene expression inhibition was further improved when the CDs were functionalized with amine functionalities at positions C2 and C3.

Modification of the secondary side of γ-cyclodextrins with two sets of primary amine functionalities via a thiopropyl linker, as compared to a triazole linker, achieved up to 80% gene knockdown, regardless of dose.

Ayse Kont, Monique Mendonça, PhD, Milo Malanga PhD, Kristóf Felegyi, Andrew Lindsay, Michael Cronin, Mary Cahill, Caitriona O’Driscoll

Structure-activity relationship of modified amphiphilic cationic cyclodextrins for enhanced siRNA delivery – ScienceDirect

cyclodextrin, cationic, carbohyde

Active transfection of genetic materials using cyclodextrin-anchored nanovectors

Today's cyclodextrin,

Today’s cyclodextrin is some gene delivery again, as it is also a focus project at CarboHyde.

Today’s cyclodextrin is some gene delivery again, as it is also a focus project at CarboHyde.

Gene-based therapy is a sophisticated means for the treatment of various complex diseases like AIDS, cancer, etc., as it resolves the genetic malfunction at the source instead of tackling the superficial symptoms. However, the therapeutic, diagnostic, and theranostic potential of gene-based therapeutic actives such as siRNA, mRNA, pDNA, aptamers, etc. is hindered by physicochemical as well as physiological barriers in the form of insufficient bioavailability, systemic metabolism, rapid renal clearance, inefficient carrier systems, etc.

This review article by Amey Revdekar, Bhagyashree Salvia and Pravin Shende features cyclodextrins and associated successful applications as the integral components of non-viral nanovectors such as cationic polymers, dendrimers and polyrotaxanes as well as supramolecular assemblies for efficient delivery of RNA-, DNA- and aptamer-based genetic payloads for the achievement of desired treatment outcomes.

Active transfection of genetic materials using cyclodextrin-anchored nanovectors – Materials Advances (RSC Publishing)

cyclodextrin